Background: Skin and soft tissue infections (SSTIs) are caused by bacterial invasion of the skin and underlying soft tissues and can present with a wide spectrum of signs, symptoms and illness severity. They are a common indication for antimicrobial therapy. However, there are few data on treatment outcomes or the validity of clinical severity scores.
Introduction
Skin and soft tissue infections (SSTIs) are clinical entities of variable presentation, aetiology and severity that involve microbial invasion of the layers of the skin and underlying soft tissues. SSTIs range from mild infections, such as pyoderma, to serious life-threatening infections, such as necrotizing fasciitis. 1 These infections lead to considerable morbidity 2 and are the indication for a significant proportion of antimicrobials prescribed in hospital. In a point prevalence survey of antibiotic use in 20 hospitals across Europe in 2006, SSTI was the second commonest indication for antibiotic treatment, after lower respiratory tract infection (LRTI). 3 However, in comparison with LRTI and community-acquired pneumonia where guidelines are founded on a large evidence base from prospective cohort studies, 4 there is little evidence about the use of clinical scores to assess severity, predict outcome or to guide therapy. Practice guidelines for SSTI from the USA 2 and the UK, 5 and an evidence review of cellulitis and erysipelas, 6 did not identify any cohort studies of management or outcome of patients hospitalized with SSTI, other than erysipelas or necrotizing fasciitis. 7 -11 More recently, one large retrospective cohort study looked at failure of antimicrobial therapy in SSTIs. 12 The UK guidelines (CREST Guidelines on the Management of Cellulitis in Adults) 5 advise on appropriate site of care, choice of antimicrobial and route of drug administration, depending on the clinical severity, stratified by Eron score, 13 which was devised from the recommendations of an expert panel.
To our knowledge, there is no validated severity grading system that predicts clinical outcome in SSTIs, along the lines of that for community-acquired pneumonia. 4 There is no previously published clinical study of outcomes in relation to severity classification. A new algorithm has recently been proposed to assess severity of SSTIs and guide therapy, based on clinical presentation, co-morbidity, and the anatomical region and size of the affected body area. 1 It seems potentially useful but requires further study and validation.
The aim of this study was to devise an operational, clarified modification of the Eron classification 13 and to apply it to a cohort of hospitalized patients with SSTI. The objectives were to compare antimicrobial management with the recommendations in the UK guideline 5 and to assess the relationship between severity (as stratified by our modification of the Eron classification), management and outcomes.
Methods

Ethics statement
Ethics committee approval was not required for this study as data were from electronic and paper hospital records. The protocol was approved by the Caldicott Guardian for hospital inpatients.
Study population and design
The study population was residents of Tayside aged ≥18 in 2005 who had a new admission to Ninewells Hospital between 1 January and 31 December 2005. The design was a retrospective cohort study of patients who received antibiotic treatment for SSTI while in hospital. Patients for whom treatment of the SSTI was not the primary reason for admission (e.g. admitted due to co-existing illness or difficult social circumstances) were included. All hospitalizations of patients aged ≥18 were examined from the Scottish Morbidity Record of hospital admissions (SMR01) database over the period January-December 2005 along with records from other linked datasets.
Case identification
The original aim was to extract clinical data from a balanced sample of 200 cases of SSTI, made up of 100 patients with blood cultures taken plus 100 patients without. Previous studies suggest that patients with blood cultures taken are more likely to have sepsis and worse outcome compared with those patients without blood cultures. 14, 15 It was expected, therefore, that including 100 of each would provide enough patients, distributed across the severity classes, to allow comparison of their treatment and outcomes. The ICD10 discharge code group used for SSTI was based on an ICD9 code list used in a previous study conducted by Johnson and Johnson, and is also similar to an ICD9 code list in a published study. 12 These included discharge codes for postoperative infections, but not for necrotizing fasciitis (M72.6), in line with a previous study, 12 as this is often considered a distinct clinical entity. Patients in the study were identified from four mutually exclusive groups. For groups (i) -(iii), random samples from all patients in the database who met the criteria were selected for case-note review.
(i) Patients with a study discharge diagnosis for SSTI (ICD10 codes L03X,  L030-3, L038-9, L97X, M608, M860-9, R02X, S913, T131, T814,  T874) who had blood cultures taken.
(ii) Patients with the above ICD10 discharge diagnoses but who did not have blood cultures taken. (iii) Patients who had blood cultures taken but did not have the above SSTI discharge codes (because we did not know how sensitive our discharge code group would be). (iv) Additional cases were identified opportunistically during screening for another study of patients aged ≥65, who had microbiology samples taken during an admission to hospital in Tayside in 2005 with at least one ICD10 discharge code indicating infection (from a predefined list, which included the above SSTI codes).
Data extraction
Case notes were reviewed to extract evidence of SSTI (a written diagnosis of SSTI in the case notes plus antimicrobial treatment), the data required to determine illness severity and the prescribed antimicrobial therapy. Co-morbidity data were also extracted to allow calculation of a Charlson index for each patient, 16 and to record the presence of diabetes mellitus because some guidelines list diabetes as a factor that may influence outcome. 2 Results of microbiology tests were retrieved from Central Vision, the electronic data management system used in NHS Tayside. These included culture and susceptibility testing of blood and wound swab cultures taken during the index admission.
Data linkages
Patient data were linked by unique community health index (CHI) number across three electronic databases, with all other data extracted from hospital case notes.
(i) CHI number database. Patient demographics (age, gender, place of residence, socio-economic status) were extracted. (ii) Scottish Morbidity Record set of databases. Those relevant to this study were the SMR 01 (General acute inpatient and day case discharges) and GRO(S) (death registrations) databases. (iii) Central Vision data management system of all laboratory tests performed in NHS Tayside. Microbiology data were extracted from Central Vision. Details included date of test, sample type, anatomical site and results of culture and susceptibility testing.
Case definitions for severity classification
Severity classification in the study was based on a modification of the Eron classification, which was used in the CREST guidelines. It was felt, as has been previously recognized, that the descriptions of clinical presentations in the Eron classification system are ambiguous. 1 This could make classification of a patient's illness severity unclear and subjective so, for this study, the definitions of severity class were modified to include only objective criteria that made the classes mutually exclusive.
An internationally recognized definition of sepsis, consisting of the systemic inflammatory response syndrome, SIRS (¼ two or more of the following criteria: white blood cell count ,4 or .12/mm 3 , temperature ,36 or .388C, heart rate .90 beats/min, respiratory rate .20 breaths/min), plus infection was used in the modified severity classification. 17 Poorly defined, outdated clinical descriptions such as the 'sepsis syndrome', 17 which defined Eron class IV, were excluded from the study definitions. 'Sepsis syndrome' is not a term used in medical documentation in the study hospital, and does not have a specific definition, so an alternative definition for class IV was devised. A standardized early warning score (SEWS) 18 of ≥4 in a patient with sepsis was used to indicate the most severely unwell patients (class IV). The SEWS is calculated, on the patient's routine clinical observations chart, by Marwick et al. summing any 'scores' allocated for abnormal clinical measurements (Table 1) . A cut-off of ≥4 was chosen as this score mandated urgent medical review of the patient, across the study NHS trust, and has been demonstrated to predict in-hospital mortality and length of stay for general medical patients. 18 Definitions of severity classes used in CREST and in the study Class I: CREST definition, patients have no signs of systemic toxicity and no uncontrolled co-morbidities; and study definition, no recorded significant co-morbidity (peripheral vascular disease, chronic venous insufficiency or morbid obesity), no sepsis and SEWS, 4.
Class II: CREST definition, patients are either systemically ill or systemically well but with co-morbidity such as peripheral vascular disease, chronic venous insufficiency or morbid obesity, which may complicate or delay resolution of their infection; and study definition, documentation of one or more significant co-morbidities (peripheral vascular disease, chronic venous insufficiency or morbid obesity) but no sepsis and SEWS,4.
Class III: CREST definition, patients may have a significant systemic upset such as acute confusion, tachycardia, tachypnoea or hypotension or may have unstable co-morbidities that may interfere with response to therapy or have a limb-threatening infection due to vascular compromise; and study definition, sepsis but SEWS, 4.
Class IV: CREST definition, patients have sepsis syndrome or severe life-threatening infection such as necrotizing fasciitis; and study definition, sepsis with SEWS≥4.
Classification of antibiotic treatment
The initial antimicrobial therapy prescribed for each patient was compared with the recommendations of the CREST Guidelines on the Management of Cellulitis in Adults, published by the Department of Health and Social Security (DHSS), Northern Ireland (June 2005). 5 These guidelines are based on the Eron classification of severity 13 and are used across the UK. They were in use in the study hospital in 2005. In this study, the modified severity classes I-IV (above) were used in place of Eron severity classes I-IV. Therapy was classified as appropriate, undertreatment or over-treatment according to the recommendations of the CREST guidelines. Where the specific antimicrobials prescribed did not feature anywhere in the CREST guidelines, the following rationale was used to classify the appropriateness of the prescribed antibiotic regimen for that severity class, based on the most likely causative organisms.
Class I: appropriate¼oral therapy active against Streptococcus pyogenes and Staphylococcus aureus; over-treatment¼any intravenous therapy OR oral therapy with unnecessarily broad-spectrum cover; and under-treatment¼oral therapy not sufficiently active against S. pyogenes and S. aureus.
Class II: appropriate ¼intravenous therapy active against S. pyogenes and S. aureus; over-treatment¼intravenous therapy with unnecessarily broad-spectrum cover; and under-treatment¼any oral therapy OR intravenous therapy that is not sufficiently active against S. pyogenes and S. aureus.
Class III: appropriate¼intravenous therapy active against S. pyogenes and S. aureus; over-treatment¼intravenous therapy with unnecessarily broad-spectrum cover; and under-treatment¼any oral therapy OR intravenous therapy that is not sufficiently active against S. pyogenes and S. aureus.
Class IV: appropriate¼intravenous therapy active against S. pyogenes, S. aureus, Gram-negative bacteria and anaerobic bacteria that included a drug that reduces toxin production by S. pyogenes (clindamycin or linezolid);
2 and under-treatment¼any oral therapy OR intravenous therapy not sufficiently active against the full range of potential pathogens and their toxins. 2 Appropriateness of first-line antimicrobial therapy by clinical severity, using the above rationale, was assessed independently by two Infectious Diseases specialists (P. D. and C. M.) and agreement on each item of data was recorded. Disagreements were resolved by discussion.
In addition to clinical appropriateness, the appropriateness of antimicrobial therapy according to the results of microbiological tests was classified. This analysis was restricted to the organisms implicated as the cause of the SSTI. First, only isolates from blood culture or from swabs of infected wounds, including ulcers, were considered. Secondly, only samples taken within 7 days before to 7 days after starting antimicrobial therapy for the SSTI were included. Thirdly, only clinically significant isolates were included, defined as any organism other than coagulase-negative staphylococci or diphtheroids from blood cultures, and only S. aureus or streptococci from wound swabs.
Full susceptibility data for implicated organisms (meeting the above criteria) were obtained from Medical Microbiology. The results on Central Vision are reported selectively; for example, the susceptibility of S. aureus to ciprofloxacin is not reported for all isolates on Central Vision. Initial antimicrobial therapy was coded as microbiologically appropriate if all significant bacterial isolates from a patient were susceptible to at least one of the antimicrobials in their initial therapy. 
Data analysis
The distribution of continuous variables was checked for skewness and, when appropriate, mean and standard deviations were reported. Otherwise, median and inter-quartile ranges were stated. Differences in proportions between groups were examined using the appropriate x 2 tests or tests for trend. Differences in continuous variables used independent Student's t-test or ANOVA, after ensuring any assumptions had been met. Inter-rater reliability between the Infection specialists for assigning appropriateness of first-line therapy by infection severity was examined with the two-way kappa test. 19 Demographic and clinical variables, along with severity class, were evaluated for effect on 30 day mortality, using univariate and multivariable logistic regression. All analyses were performed using Stata version 9.0 or Microsoft Excel.
Results
Case identification
In total, 205 valid cases of SSTI were identified from the four mutually exclusive patient groups described above. Eighty-two (76%) of 108 patients screened in the group with SSTI discharge codes and blood cultures taken were valid cases. A similar number were identified from the group with SSTI discharge codes but without blood cultures taken, where 84 (81%) of 104 cases screened were valid. Screening of 112 sets of case notes from the third group, without SSTI discharge codes but with blood cultures taken, only identified seven (6%) valid cases. Thirty-two additional cases, meeting the study definition for SSTI, were opportunistically identified during screening of case notes for another study. Five of these patients had ICD10 codes in the study SSTI code group and 13 had other codes indicating infection or inflammation of the skin, not included in our original SSTI group. Fourteen had no discharge codes indicating SSTI, but six of these had blood cultures taken and two had non-site-specific infection codes, for e.g. infection following a procedure.
Of the final 205 valid cases of SSTI, 107 had no blood culture and 98 had one or more blood cultures taken (Table 2) . Full data about the initial antimicrobial regimen were not available for 16 patients so analysis of the appropriateness of treatment was done on 189 patients. Antibiotic treatment was started in the first 2 days of hospitalization in 161 (85%) of these patients. In the remaining patients antibiotic treatment was started a median of 10 days after admission, range 3 -75 days.
Patient demographics and clinical description
There were no statistically significant differences in demographic characteristics between patients with and without blood cultures (Table 2 ). In-hospital mortality was 8% (17/205) for the cohort, and 30 day mortality was 9% (18/205). There was no significant difference in mortality between those patients with and without blood cultures taken ( Table 2) .
The majority of patients (81%) were admitted from their own home. Others were admitted from residential or nursing homes (11%) or transferred from other hospitals (5%). The source of admission for five patients (2%) was unknown. Most patients were admitted to General Medicine (n¼ 100, 49%) or General Surgery (n¼ 51, 25%). The remaining patients were admitted to specialist medical wards (n¼28, 14%) orthopaedics and trauma surgery (n¼ 16, 8%) or specialist surgical wards (n¼ 20, 10%). Length of stay ranged from 1 to 226 days with a highly skewed distribution: mean 18 days, median 2 days.
Of the 205 study patients, 92 (45%) patients were in severity class I, 66 (32%) in class II, 35 (17%) in class III and 12 (6%) in class IV. Unadjusted mortality at 30 days significantly increased with severity class but readmission did not vary. Crude 30 day mortality rates were 1% (1/92) in class I, 11% (7/66) in class II, 17% (6/35) in class III and 33% (4/12) in class IV (x 2 test, P,0.001).
Thirty-eight patients (19%) had diabetes mellitus. In comparison with class I patients, there were substantially more patients with diabetes in class II (28/66, 42% compared with 2/92, 2%). However, the proportion of diabetics in classes I and II combined (30/158, 19%) was similar to the proportion in classes III and IV combined (8/47, 17%). Logistic regression, with diabetes as an independent risk factor, did not show any significant effect of diabetes on 30 day mortality, either unadjusted (odds ratio 1.13, 95% CI 0.98-1.31), or adjusted for age, sex, Charlson Marwick et al.
index of co-morbidity, severity class and treatment (odds ratio 1.13, 95% CI 0.92-1.40).
Antimicrobial therapy
The 189 patients for whom full prescription data were available received a total of 35 different antibiotic regimens (45 if route of administration is also considered), resulting in 79 different combinations of severity class and antibiotic regimen. Most patients (133, 70%) received a b-lactam antibiotic. The initial antibiotic regimen was monotherapy in 143 (76%), two drugs in 43 (23%) and three drugs in 3 (2%) patients. Full details of all regimens prescribed, by severity class, are in Table 3 . In general, the spectrum of initial therapy increased with severity. However, only 52 (29%) of 177 patients in classes I -III received flucloxacillin alone as recommended in the CREST guidelines, 5 whereas 33% (4/12) of patients in class IV were initially treated with flucloxacillin alone.
Inter-rater agreement on appropriateness (by CREST guidelines)
Agreement between raters about the appropriateness of each combination of antibiotic regimen and severity class was 85% (67/79), two-way kappa ¼ 0.61 (95% CI 0.41-0.80, P,0.01) indicating substantial agreement. In the 12 instances of disagreement, three were under-treatment versus appropriate, and nine were over-treatment versus appropriate. The three regimens considered under-treatment, for that severity class, by one rater were: intravenous erythromycin for class II, clindamycin and metronidazole for class IV, and intravenous clarithromycin for 0  9  benzylpenicillin  iv  flucloxacillin  iv  over  0  1  ceftazidime  iv  metronidazole  iv  over  0  2  ceftriaxone  iv  over  0  2  cefuroxime  iv  metronidazole  iv  over  0  2  cefuroxime  iv  over  0  1  ciprofloxacin  po  clindamycin  iv  over  0  2  ciprofloxacin  po  clindamycin  po  over  0  5  clindamycin  iv  over  0  1  co-amoxiclav  iv  flucloxacillin  iv  over  0  1  co-amoxiclav  iv  metronidazole  iv  over  0  5  co-amoxiclav  po  over  1  9  co-amoxiclav  iv  over  0  16  flucloxacillin  iv  over  0  1  piperacillin/tazobactam  iv  over  0  3  cefalexin  po  under  0  1  ciprofloxacin  iv  under  0  7  ciprofloxacin  po  under  0  1  metronidazole  po  under  0   Severity class II  2  benzylpenicillin  iv  flucloxacillin  iv  appropriate  1  1  ceftriaxone  iv  appropriate  0  2  clindamycin  iv  appropriate  0  2  clindamycin  po  appropriate  0  12  flucloxacillin  iv  appropriate  0  1  vancomycin  iv  appropriate  0  1  ceftriaxone  iv  flucloxacillin  iv  metronidazole  iv  over  0  2  cefuroxime  iv  over  1  1  ciprofloxacin  po  clindamycin  po  rifampicin  po  over  0  1  ciprofloxacin  iv  clindamycin  iv Severity class IV  1  clindamycin  iv  levofloxacin  iv  metronidazole  iv  appropriate  0  1  ciprofloxacin  po  under  0  1  clarithromycin  iv  co-amoxiclav  iv  under  0  1  clindamycin  iv  metronidazole  iv  under  1  1  clindamycin  po  under  0  1  co-amoxiclav  iv  under  0  4  flucloxacillin  iv  under  0  1  metronidazole  iv  under  0  1  vancomycin  iv  under  0  189  12 iv, intravenous; over, over-treatment; po, oral; under, under-treatment.
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class III. The resolution was to code the first two regimens as under-treatment and the third as appropriate treatment. Eight of the nine regimens rated as over-treatment by one rater involved patients in classes I-III who received co-amoxiclav, ciprofloxacin or cefuroxime, with or without the addition of flucloxacillin. The resolution was to code all eight as over-treatment. The final case of disagreement about over-treatment involved a patient in class II who received intravenous flucloxacillin plus benzyl penicillin. The resolution was to code this as appropriate. Consensus decisions on the appropriateness of each prescribed antibiotic regimen by severity class, and whether or not there was initial disagreement, are detailed in Table 3 .
Appropriateness (by CREST guidelines) of therapy by severity class
Overall, only 26% of patients received antibiotics classified as appropriate ( Table 4 ). The prevalence of over-treatment was inversely related to and the prevalence of under-treatment was positively associated with increasing severity class ( Table 4 ). Only one of 12 (8%) patients in class IV received empirical treatment that was likely to cover all potential pathogens and toxins (clindamycin plus levofloxacin plus metronidazole). Seven patients received regimens with significant gaps in antimicrobial spectrum (narrow-spectrum penicillins alone, metronidazole alone, ciprofloxacin alone or vancomycin alone), and one patient received intravenous co-amoxiclav, which we did not regard as adequate therapy for severe sepsis with SSTI. In addition, two patients received oral therapy. Even in class I infections 10% of patients received oral therapy that is not sufficiently active against S. pyogenes and S. aureus (ciprofloxacin alone or metronidazole alone).
Microbiology results and resistance
There were 43 clinically significant bacterial isolates from specimens taken within 7 days of start of antimicrobial therapy from 33 patients. Three isolates were from blood cultures (S. aureus n¼ 2, Bacteroides fragilis n¼1). All of the remaining isolates were S. aureus from wound swabs. There were 20 patients with one or more isolates of methicillin-susceptible S. aureus (MSSA) and 12 patients with one or more isolates of methicillin-resistant S. aureus (MRSA). Patients with MRSA were more likely to receive microbiologically inappropriate therapy, with isolates being resistant to initial therapy in 6/12 (50%) patients with MRSA versus 3/20 (15%) patients with MSSA, odds ratio 5.67 (95% CI 1.07 -30.09). The patients with MSSA that was resistant to initial therapy received benzylpenicillin (n¼ 1), clarithromycin (n¼ 1) or ciprofloxacin (n¼ 1). The patients with MRSA that was resistant to initial therapy received co-amoxiclav (n¼ 3), clindamycin (n¼ 2) or cefuroxime (n¼ 1). The patients with MRSA that was susceptible to empirical therapy received gentamicin (n¼ 2), ciprofloxacin plus clindamycin (n¼ 1), fusidic acid (n¼ 1), trimethoprim plus rifampicin (n¼ 1) or vancomycin (n ¼1).
The number of patients with MRSA and MSSA in each severity class (and percentage of total patients in that class) was: class I: 4 (4%) MRSA, 13 (14%) MSSA; class II: 7 (11%) MRSA, 5 (8%) MSSA; class III: 1 (3%) MRSA, 2 (6%) MSSA. None of the patients in class IV had significant bacterial isolates.
Patients in whom antibiotic treatment for an SSTI was started .2 days after admission to hospital were more likely than those treated in the first 2 days to have MRSA [5/28 (17 
Multivariable analysis of mortality
None of the demographic variables [age, sex, Charlson index of co-morbidity, and Scottish index of multiple deprivation (SIMD)] had any significant effect on 30 day mortality, either unadjusted or adjusted, in this cohort of 189 SSTI patients (Table 5 ). There was an increase in the odds ratio for death within 30 days with each increase in severity class. Once adjusted for demographic variables and appropriateness of first-line therapy, having infections in severity class III and IV was significantly associated with increased mortality (Table 5 ). The very wide 95% confidence intervals reflect the low numbers of deaths, but there is a clear association between increasing clinical severity class and mortality. The appropriateness of treatment had no significant effect on the likelihood of death, particularly once adjusted for other variables (Table 5 ). The number of SIRS criteria a patient met did not influence 30 day mortality, either unadjusted or adjusted for demographic variables and for appropriateness of therapy (Table 5) . Because there is overlap between the SIRS criteria, the factors comprising SEWS and the study definitions of severity class, these three variables (severity class, SIRS and SEWS) were considered in separate regression models, adjusting the effect of each for the demographic variables and treatment appropriateness.
Increasing SEWS had a stepwise and significant effect on mortality, which was even greater once other factors had been adjusted for. There were insufficient numbers of outcome events to look separately at the effect of each individual clinical variable that contributes to SEWS (pulse, blood pressure, etc.; Table 1 ). Even the odds ratios for the effect of total SEWS on 30 day mortality had very wide 95% confidence intervals (Table 5) .
Discussion
SSTIs are common, with Hospital Episode statistics in the UK recording 69 576 admissions with a diagnosis of cellulitis in 2004-05. 6 Therefore, it is surprising that there is very little Uncertainty among doctors about appropriate empirical antimicrobial treatment of SSTIs is demonstrated by the 35 different antibiotic regimens prescribed in this cohort study. This is only slightly less practice variation than the 46 different empirical regimens reported in a retrospective cohort study of 47 219 patients with SSTI from .400 hospitals in the USA. 12 To our knowledge this is the first published study to evaluate the relationship between empirical treatment and a severity classification in SSTIs. The study definitions for each severity class were adapted from those published in a set of UK guidelines 5 to make the criteria more objective and to ensure that the four classes were mutually exclusive.
For class II, the CREST guidance recommends intravenous therapy due to the presence of specified co-morbidities that 'may complicate or delay resolution of their infection'. However, our data showed little difference between classes I and II in Separate regression models were created for SIRS criteria and for SEWS with the same co-variates, with the exception of severity class. None of the co-variates in these two additional models had statistically significant odds ratios (data not shown).
terms of antimicrobial therapy, over half of which was intravenous in both of these classes, or adjusted outcome. Likewise, a randomized trial of intravenous versus oral therapy in 60 patients with erysipelas without complications showed no clinical benefit of intravenous therapy as evaluated by fever duration, hospital stay and sick leave. 20 These data question whether classes I and II could actually be merged, with severity assessment and treatment decisions based on clinical parameters (SIRS and SEWS), rather than also considering co-morbidity. Accordingly, the SSTI management guidelines in our NHS trust have been changed due to the findings of this study, and now include only three severity classes, with oral therapy recommended for the least severe class (which includes patients who would previously have been in class II).
The presence of sepsis in association with SSTIs, even without more severe physiological upset (i.e. severity class III), was associated with worse outcome than having no sepsis (classes I and II), consistent with existing evidence. 17, 21 While the actual number of SIRS criteria met did not appear to have an effect on mortality, meeting two or more criteria, which in the context of infection means sepsis (and in this study means severity class III) is associated with increased mortality (Table 5 ).
Severity class IV should include patients with severe sepsis, the CREST definition for class IV being 'sepsis syndrome or severe life-threatening infection'. The accepted definition of severe sepsis is sepsis complicated by organ dysfunction, 22 but different systems can be used to define organ dysfunction 22 and, particularly in a retrospective observational study, these can be difficult to apply. In this study, the SEWS system (Table 1) , which was designed to identify patients at risk of cardiac arrest and death in hospital, 18 was used to classify the most severely ill patients (class IV) as those with a SEWS of ≥4. A previous study demonstrated that a SEWS of ≥4 on admission to hospital predicted in-hospital mortality and length of stay for general medical patients. 18 SEWS charts were in use across our NHS trust at the time of the study so these data were available for all patients. Also, there was an agreed hospital-wide policy that mandated urgent medical review for any patient with a SEWS of ≥4, 24 h a day, 7 days a week. The significantly greater mortality in our class IV patients, and the stepwise increase in mortality with increase in SEWS ( Table 5 ), suggest that SEWS could have a role in identifying the highest risk patients and guiding the use of intensive therapy in SSTIs. While we had insufficient outcome events to examine the effect of the individual components of the SEWS, the total score is potentially more clinically useful, although limits generalization to other early warning scoring systems. The relative importance of each SEWS component, and the cut-off values that best predict outcome in different clinical contexts, is the subject of a recent investigation. 23 Again, a prospective study in SSTI patients is required to evaluate this, and to assess any added value of risk scores based on laboratory tests. 11 The level of agreement between two independent raters on appropriateness of treatment by clinical severity achieved in this study was high at 85%, much higher than we have found in previous work. 19 This is most likely due to the fact that we stipulated a priori what would and would not be considered appropriate therapy, based on CREST guideline recommendations, for each severity class. What constitutes appropriate therapy in a given clinical situation can be very difficult to define. Even in bacteraemic patients, the relationship between 'appropriate' therapy and outcome in staphylococcal infections is unclear. 24 Further difficulties in assessing appropriateness arise as a result of the changing clinical and political climate. During the study period, our antibiotic policy recommended including ciprofloxacin for severity class IV patients, but this has now changed because of increasing concerns about Clostridium difficile. Consistency and transparency in evaluation of appropriate therapy in trials of therapy-related outcomes are essential. 25 Under-treatment, according to clinical severity, was associated with greater mortality but the association was not significant. There are two potential explanations. First, in 34% (20/58) of patients coded as under-treated this was because they received oral therapy for class II, which may actually be as effective as intravenous treatment. 20 Second, our study data do not allow assessment of outcome by treatment in classes III and IV because only one patient in class IV received appropriate antimicrobial therapy. Consequently, more data are required from prospective studies to fully define the relationship between empirical therapy and outcome.
A conservative approach to the microbiology of SSTI was taken, and only blood culture isolates (other than coagulasenegative staphylococci) and S. aureus isolates from wound swabs were included (there were no streptococci isolated from study patients in the defined time period). Even with this conservative approach the proportion of patients with bacteria resistant to empirical therapy was high (9/33, 27%) because of the local prevalence of MRSA, which is similar to other UK centres. It is perhaps surprising, therefore, that CREST guidance does not recommend MRSA cover for even the most severely ill patients. 5 This is partly explained by the lower prevalence of MRSA when and where (Northern Ireland) the guidance was written but, even in the USA where, particularly community-acquired, MRSA is more prevalent, the evidence for empirical coverage is not conclusive. One published study has found a non-significant trend towards poorer outcome in SSTI when MRSA was not covered at the outset. 12 Most MRSA in the UK is healthcare associated. Many patients admitted to hospital have significant previous healthcare exposure and the factors required for risk stratification for MRSA 26 -28 may not be immediately available on presentation to hospital. While it seems intuitive that early appropriate therapy improves outcome, and therefore that patients with SSTI and sepsis should receive empirical coverage of MRSA, the evidence for this approach comes from other disease entities and no such studies exist for SSTI. 29 Strengths of our study are that we used an electronic database to randomly sample patients for screening. We were also able to obtain additional data from case notes, including indicators of severity of infection and data from microbiology specimens collected within 7 days of the start of antimicrobial therapy. These data have enabled analysis of appropriateness of initial therapy adjusted for severity of illness, which was not possible in a large retrospective study of SSTI from an administrative database. 12 The principal weaknesses of our study are common to any retrospective study and include errors of omission in coding and the consequent risks of sampling bias as well as the inability to adjust for confounding by variables that are not reliably collected in case notes. 12 Also, we included patients who did not meet the original sampling criteria, but whose case notes were screened for a different study and met the SSTI study definition. This introduces further risk of sampling bias. Significant bacterial isolates were only cultured from 33 (16%) of all 205 patients, and only 3 (6%) of the 47 more severely ill patients in classes III and IV, so we could not analyse outcome by pathogen. This is common to studies of SSTI where cultures are often of low yield, so treatment has to be based on the likely pathogens rather than the individual patient's microbiology results. 1, 30 Other weaknesses are that we did not study any potential effects of time to antibiotic administration, or of antibiotic dosing, on patient outcome. Time to antibiotics can influence outcome in severely ill septic patients 31 so is a potential source of confounding in relation to class IV. Underdosing could also adversely affect outcome and, although drug dosing tends to be standard across our hospital, we did not specifically look at any effect of dose variation on outcome. Also, we did not record potential adverse effects of antibiotic therapy, such as C. difficile-associated diarrhoea, or the isolation of resistant pathogens following treatment.
This study has added to the case for clinical trials to compare selection of antimicrobial drug and route of administration in SSTI, which was the conclusion of a recent review of the evidence. 6 Two research questions could potentially be addressed in a single trial. First, is intravenous therapy given first-line more effective than oral therapy for patients without systemic inflammatory response? Second, is empirical therapy with activity against MRSA more effective than flucloxacillin for patients with systemic inflammatory response?
To inform the design of a clinical trial, data from prospective cohort studies in targeted clinical settings, e.g. acute medical admissions or acute surgical admissions, are required in order to assess likely recruitment rates and perform power calculations for a randomized trial. Prospective data on microbial pathogens and validation of proposed clinical severity scoring systems would also be required. In particular, evidence is required about the predictive value in SSTI of laboratory tests that have been shown to predict outcome in necrotizing fasciitis 8, 10, 11 or severe sepsis. 21 The measurement of clinical outcome in trials of therapy in SSTI requires careful consideration given the heterogeneity of clinical presentation, and correspondingly different associated mortality rates. 30, 32 A recent review of historical literature from the immediately pre-and post-antibiotic eras described the untreated mortality of cellulitis/erysipelas as 11%, and major abscess as 6%, 32 with the recommendation that measures of outcome in trials should be weighted according to the specific type of SSTI. 30, 32 Also, given that the mortality associated with SSTIs is low in the antibiotic era, 32 other measures of clinical failure of therapy must be defined and agreed for more informative comparison of antimicrobial agents in clinical trials. 30, 33 In conclusion we have shown that patients with SSTIs and a systemic inflammatory response have significantly worse outcomes than other patients with SSTIs. The majority of these patients receive clinically inadequate antimicrobial therapy with the currently recommended treatment for class IV being broadspectrum and intravenous. The optimal choice of antimicrobial therapy, and whether this includes coverage for MRSA, requires review and definitive study in clinical trials.
